Microbio (4128) Fundamentals 2026 — Revenue Analysis | SniperIQ
Microbio (4128) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$9.0B, trading at NT
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Microbio's market cap?
Microbio (4128) has a market capitalization of approximately NT$9.0B, trading at NT
What is Microbio's P/E ratio?
Microbio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Microbio?
Microbio runs a net profit margin of -35.7%, a gross margin of 36.6%, and an operating margin of -22.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Microbio generate?
Microbio reported revenue of NT
Does Microbio pay a dividend?
Microbio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Microbio financially healthy?
Microbio carries a debt-to-equity ratio of 0.07x and a current ratio of 5.76x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Microbio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Microbio (4128) the key facts are: market cap NT$9.0B, revenue NT
Track Microbio's full fundamentals live
Get Microbio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.